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Abstract
The transitions between developmental stages are critical points in the Plasmodium life
cycle. The development of Plasmodium in the livers of their mammalian hosts bridges
malaria transmission and the onset of clinical symptoms elicited by red blood cell infection.
The egress of Plasmodium parasites from the liver must be a carefully orchestrated process
to ensure a successful switch to the blood stage of infection. Cysteine protease activity is
known to be required for liver-stage Plasmodium egress, but the crucial cysteine protease
(s) remained unidentified. Here, we characterize a member of the papain-like cysteine prote-
ase family, Plasmodium berghei serine repeat antigen 4 (PbSERA4), that is required for effi-
cient initiation of blood-stage infection. Through the generation PbSERA4-specific antisera
and the creation of transgenic parasites expressing fluorescently tagged protein, we show
that PbSERA4 is expressed and proteolytically processed in the liver and blood stages of
infection. Targeted disruption of PbSERA4 results in viable and virulent blood-stage para-
sites. However, upon transmission from mosquitoes to mice, Pbsera4(-) parasites displayed
a reduced capacity to initiate a new round of asexual blood-stage replication. Our results
from cultured cells indicate that this defect results from an inability of the PbSERA4-deficient
parasites to egress efficiently from infected cells at the culmination of liver-stage develop-
ment. Protection against infection with wildtype P. berghei could be generated in animals in
which Pbsera4(-) parasites failed to establish infection. Our findings confirm that liver-stage
merozoite release is an active process and demonstrate that this parasite-encoded cysteine
protease contributes to parasite escape from the liver.
Author summary
Plasmodium parasites cause over 200 million cases of malaria every year. When parasites
are transmitted by mosquito bite, they initially colonize the liver before they move into
PLOS PATHOGENS
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008891 September 21, 2020 1 / 20
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Putrianti ED, Schmidt-Christensen A,
Heussler V, Matuschewski K, Ingmundson A
(2020) A Plasmodium cysteine protease required
for efficient transition from the liver infection stage.
PLoS Pathog 16(9): e1008891. https://doi.org/
10.1371/journal.ppat.1008891
Editor: Scott E. Lindner, Pennsylvania State
University University Park: Penn State, UNITED
STATES
Received: July 14, 2020
Accepted: August 15, 2020
Published: September 21, 2020
Copyright: © 2020 Putrianti et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: This work was supported by the
European Commission (EC):Kai Matuschewski
EviMalaR,#34; Deutsche Forschungsgemeinschaft
(DFG):Volker Heussler HE 4497/1-2; Deutscher
Akademischer Austauschdienst (DAAD):Elyzana
Dewi Putrianti. The funders had no role in study
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
7
0
6
3
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
the blood and cause disease. During successful transition from the liver into the blood,
Plasmodium cloak themselves in host plasma membrane as they egress from the liver cells.
Although some aspects of how Plasmodium exit their host hepatocytes appear unique, cer-
tain attributes are shared across diverse pathogens. For example, protease activity is
required not only for multiple stages of Plasmodium exit, but is also involved in the egress
of some bacteria and other protozoan. Here we characterize a protease in Plasmodium ber-
ghei that is expressed in the liver and conserved across Plasmodium species. Through gene
targeting, we found PbSERA4 is required for efficient egress of Plasmodium from the
liver. In the absence of this protease the transition between the liver and blood stages of
growth is prolonged due to inefficient parasite release from liver cells. These findings pro-
vide new insights into the function of a conserved Plasmodium protease and into the pro-
cess of Plasmodium escape from the liver.
Introduction
For a parasitic disease to be maintained in a population, each step of an often complex life
cycle must be sustained, and successful transitions between these steps are essential. Plasmo-
dium parasites, which are responsible for malaria, alternate between a vertebrate and an insect
host. Inside the vertebrate hosts, Plasmodium parasites enter suitable target cells and prolifer-
ate within an intracellular compartment termed the parasitophorous vacuole [1, 2]. As a conse-
quence, parasites have to actively enter and exit their host cell in order to progress in the life
cycle. Pathogen exit from host cells is a complex series of events, typically involving both path-
ogen-encoded factors as well as host-derived proteins [3, 4].
A hallmark of the Plasmodium life cycle in the mammalian host is the initial obligatory par-
asite population expansion phase inside the mammalian liver. Prior to the pathogenic asexual
parasite propagation in red blood cells, Plasmodium parasites infect hepatocytes, where they
transform from the motile sporozoite transmission form into spherical trophozoites that initi-
ate multiple rounds of closed mitosis and form thousands of first-generation liver-stage mero-
zoites [5, 6]. In order to egress from the liver, these merozoites escape the parasitophorous
vacuole to the host hepatocyte cytoplasm, which requires a Plasmodium phospholipase [7, 8].
Upon parasitophorous vacuole membrane breakdown, the host cell architecture is altered to
allow the budding of host-cell-derived extracellular vesicles containing infectious merozoites
[7, 9]. These so-called merosomes emerge directly into the liver sinusoids and arrest in the
lung capillaries where merozoites are discharged and invade neighboring erythrocytes to com-
mence blood infection [6], the exclusive cause of clinical malaria symptoms.
Inhibitor studies revealed a crucial role for cysteine protease activity in egress of either
liver-stage or blood-stage merozoites [7, 10–13], but the identity of the essential liver-stage cys-
teine proteases remains undetermined. A family of papain-like proteases termed the serine-
rich antigen (SERA) family is encoded by all Plasmodium species and includes members that
are expressed in the liver stage of infection [10, 14]. Several of the SERA proteins are important
for exit of Plasmodium at different stages of development. For example, the Plasmodium ber-
ghei PbSERA5/ECP1 is required for egress of sporozoites from oocysts in the mosquito midgut
[15], whereas the Plasmodium falciparum PfSERA5 and PfSERA6 are important for exit of
merozoites from blood-stage schizonts [16, 17]
SERA family members have been shown to be processed by the Plasmodium subtilisin-like
protease 1, SUB1, in the parasitophorous vacuole prior to parasite egress [18]. In infected
erythrocytes, cleavage and activation of SERAs is triggered by secretion of SUB1 into the
PLOS PATHOGENS A Plasmodium cysteine protease required for efficient transition from the liver infection stage
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008891 September 21, 2020 2 / 20
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
parasitophorous vacuole. This proteolytic cascade is followed by breakdown of the parasito-
phorous vacuole and eventual release of blood-stage merozoites [11, 12]. SUB1 is not only
required for egress of blood-stage Plasmodium; P. berghei SUB1 was also shown to be essential
for liver-stage parasite egress [19, 20]. One of the SERA genes that shows high transcript levels
during late liver-stage development is PbSERA4 [10, 14]. PbSERA4 is a cysteine-type SERA
that is well conserved across the known rodent- and primate-infecting Plasmodium species
[21]. Here, targeted PbSERA4 gene disruption reveals a role for this putative protease in the
process of Plasmodium escape from the liver.
Results
The Plasmodium berghei SERA4 cysteine protease is expressed at multiple
stages in the parasite life cycle
The Plasmodium berghei PbSERA4 (PBANKA_0304800) gene encodes a cysteine-type SERA
and is conserved and syntenic across the primate and rodent Plasmodium species [21]. The
predicted orthologue of PbSERA4 in Plasmodium falciparum is PfSERA7 (PF3D7_0207400),
and the proteins encoded by these genes are 44% identical and 57% similar (Fig 1A). Within
the signature papain family cysteine protease domain (PFAM: PF00112), PbSERA4 and
PfSERA7 share 66% amino acid identity (Fig 1A) and include the strictly conserved catalytic
residues, i.e. an amino-terminal glutamine, the catalytic cysteine residue, a central histidine,
and a carboxy-terminal asparagine (Fig 1B).
To profile PbSERA4 expression throughout the Plasmodium life cycle, we employed stan-
dard RT-PCR analysis (Fig 1C and S1A Fig). PbSERA4 transcripts are detectable in blood-
stage P. berghei and can be detected in mid and late liver-stage parasites but are below the
detection threshold in early liver stages. In the insect vector, PbSERA4 transcripts can be
detected in sporozoites isolated from the midguts or salivary glands of infected mosquitoes.
Together, these data support our previous quantification of PbSERA transcripts in the mam-
malian host [10, 14] and confirm global transcript profiling data of both P. berghei [22] and P.
falciparum [23–25]. Expression of PbSERA4 in several developmental stages indicates func-
tions during multiple points of the Plasmodium life cycle.
Expression and localization of PbSERA4 in late liver-stage P. berghei
To examine protein expression and assess the localization of PbSERA4, we generated a trans-
genic P. berghei ANKA line that expresses fluorescently tagged PbSERA4 from the native
PbSERA4 promoter (S1B Fig). Diagnostic PCR confirmed the integration of the targeting vec-
tor, which results in C-terminal tagging of PbSERA4 with mCherry (S1C Fig). We then fol-
lowed the life cycle progression of the resulting transgenic PbSERA4-mCherry parasite line,
which expresses both constitutive cytoplasmic green fluorescence [26], and the red fluores-
cently tagged PbSERA4 protein. PbSERA4-mCherry parasites progressed normally through the
Plasmodium life cycle, including transmission to Anophelesmosquitoes and back to mice, indi-
cating that expression of endogenously tagged PbSERA4 is compatible with parasite viability
in all stages. Consistent with reported transcriptome data [27, 28], we detected PbSERA4-m-
Cherry signal in late asexual blood stages and gametocytes (S1D Fig), and we could observe
red fluorescence throughout exflagellation of male gametes. We failed to detect a red fluores-
cent signal in PbSERA4-mCherry sporozoites isolated from mosquito midguts or salivary
glands despite the presence of PbSERA4 transcripts (Fig 1C)[25]. We could confirm the
absence of protein expression in sporozoites using a parasite line we generated in which the
PbSERA4 promoter drives GFP expression (S2 Fig). In these parasites, low levels of GFP are
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detected in oocysts but not in sporozoites isolated from salivary glands. In contrast, GFP
expressed under control of the promoter of PbSERA5, which is known to function in the egress
of sporozoites from oocysts, is clearly detectable in sporozoites. Neither GFP expressed from
the PbSERA4 promoter (S2 Fig), nor mCherry signal in PbSERA4-mCherry parasites (Fig 2A)
could be detected in early liver-stage P. berghei. However fluorescent protein expression in
Fig 1. Plasmodium berghei SERA4 is a papain-like cysteine protease expressed across the Plasmodium life cycle.
(A) Schematic structure of P. berghei PbSERA4 (PBANKA_0304800) and its ortholog in P. falciparum PfSERA7
(PF3D7_0207400). The putative signal sequences and the central papain-like cysteine protease domains are boxed in
red and grey, respectively. Putative cleavage sites S1, S2 and S3 are as indicated at amino acids 295 (IKGEDDLD), 806
(ISGQTDNQ) and 173 (LTAKIEED), respectively. Antibodies were generated against the portions of PbSERA4
indicated by the black line labeled M. Amino acid sequence identities between PbSERA4 and PfSERA7 are indicated as
percent for both the overall sequence and the catalytic domain. (B) The catalytic residues of the papain family of
cysteine proteases are conserved in PbSERA4 and PfSERA7. Strictly conserved amino acid residues are boxed in grey,
and the putative active-site cysteine is boxed in black and marked with an asterisk. The catalytic histidine and flanking
glutamine and asparagine residues, which form the oxyanion hole, are marked with an ‘o’. Papain is from Carica
papaya. Bold numbers represent the amino acid positions within the protein before and after the catalytic domain;
numbers in parenthesis represent the number of intervening amino acids at the indicated positions. (C) Expression
profiling of PbSERA4 in P. berghei ANKA. RT-PCR analysis from mixed blood stages (BS), liver stages (at 24, 48, and
72 hours after infection), liver stage merozoites (mer), and midgut (mg) and salivary gland (sg) sporozoites. Control
transcripts were merozoite surface protein 1 (MSP1), glyceraldehyde dehydrogenase (GAPDH) or thrombospondin-
related anonymous protein (TRAP) for blood, liver, and mosquito stages, respectively. Products run at the expected
sizes in comparison to these products amplified from P. berghei genomic DNA (S1A Fig).
https://doi.org/10.1371/journal.ppat.1008891.g001
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Fig 2. Proteolytic processing and localization of PbSERA4 in late liver-stage P. berghei. (A) PbSERA4-mCherry is detected in late
liver-stage P. berghei. Huh7 hepatoma cells were infected with the PbSERA4-mCherry P. berghei ANKA line, fixed at the indicated
time points and imaged by confocal microscopy. The parasites were detected with constitutive, cytoplasmic GFP expression (green).
Scale bars, 8 μm. (B) The α-PbSERA4M antibody detects full length PbSERA4 and PbSERA4 cleavage products. Liver-stage lysates
were prepared from merosomes and detached cells (lane 1) collected from infected HepG2 cells and compared to uninfected HepG2
cells (lane 2). Proteins from mixed purified blood-stage parasites were initially solubilized with saponin and subsequently NP40 and
compared to whole-cell SDS lysates of purified mature blood-stage schizonts. The predicted catalytic domain released by proteolytic
processing is marked by the asterisk and appears to run slower in liver-stage compared to blood-stage samples. All displayed lanes are
from one gel. (C) P. berghei ANKA-infected HepG2 cells were fixed at different time points (45-58h) post infection and stained with
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both lines is evident later in the liver stage. PbSERA4-mCherry could be detected 48 hours
after infection of cultured cells with PbSERA4-mCherry sporozoites (Fig 2A). The PbSER-
A4-mCherry signal progressively increased, and late liver schizonts and liver merozoites exhib-
ited bright fluorescence.
In parallel to this tagging approach, we generated an antibody against the central domain of
PbSERA4 (α-PbSERA4M) (Fig 1A). Because the central region of the SERA proteins is rela-
tively conserved, we tested the specificity of the α-PbSERA4M antiserum against recombinant
purified central domains of the P. berghei proteins PbSERA1-4 and found α-PbSERA4M to
exclusively recognize PbSERA4 (S3 Fig). When lysates of liver-stage and blood-stage P. berghei
were probed by western blot with α-PbSERA4M, the detection of multiple fragments indicates
that, like other SERA proteins, PbSERA4 is proteolytically processed during infection. We pre-
dicted putative SUB1 cleavage sites within PbSERA4 based on the cleavage pattern of other
SERA proteins, and on the previously reported consensus recognition motif of SUB1 [18] (Fig
1A). In addition to the full-length protein, which is predicted to be 107kDa, the α-PbSERA4M
antibody recognizes a protein in the lysates of blood-stage schizonts that may represent the
central catalytic domain, which is predicted to be 59kDa, as well as an intermediate cleavage
product. If the order of PbSERA4 processing occurs as described for PfSERA5 [29, 30], we
would expect this intermediate cleavage product to represent the product C-terminal to the
predicted S1 cleavage site and have the predicted size of ~73 kDa. The intermediate cleavage
product we detected corresponds to a slightly larger size (Fig 2B and S4C Fig, arrowhead) and
could represent the N-terminal product that would be generated by cleavage only at the S2
cleavage site.
Proteolytic processing of other Plasmodium SERAs has been shown to occur in the parasi-
tophorous vacuole prior to schizont rupture [18, 31]. To biochemically distinguish the parasi-
tophorous vacuole from the parasite, purified mixed blood stages, which comprises mostly
trophozoites, were treated with saponin to lyse the red blood cell and parasitophorous vacuole
(Fig 2B). The putative catalytic domain-containing cleavage product appears in the saponin-
soluble fraction, whereas the lysate of the remaining parasite-containing fraction contained
only the full-length PbSERA4 protein. This data suggests that in blood-stage P. berghei, the
proteolytic processing of PbSERA4 occurs in the parasitophorous vacuole. We also probed
lysates from merosomes generated from sporozoite-infected hepatoma cells (Fig 2B). Here,
only one band of approximately 60kDa is detected. In contrast to the sample containing
blood-stage schizonts, we did not detect full length PbSERA4 protein. This result may be due
to greater enrichment of late-stage parasites in the merosome sample in comparison to the
blood-stage schizont sample, which contains late trophozoites and early schizonts. The band
detected in the merosomes appears to run higher on the gel than the putative PbSERA4 pro-
teolytic domain from the blood-stage parasites, which may be due to different properties of the
samples or may indicate modifications or alternate processing. We were unable to detect pro-
tein with the α-PbSERA4M antibody in late liver stage-infected cells, likely due to the low
infection rate relative to the sensitivity of the antibody. Still, these results suggest that PbSERA4
likely undergoes proteolytic processing by the end of the liver infection stage.
Using this antibody for immunofluorescence allowed detection of PbSERA4 in late liver-
stage P. berghei and direct comparison to the localization of PbSERA3, which is also abun-
dantly expressed during late liver infection [10] (Fig 2C). In P. berghei-infected hepatoma cells
α-PbSERA4M (green) in comparison to α-PbSERA3N (red), α-PbEXP1 (cyan), which labels the parasitophorous vacuole membrane
(PVM), and the DNA dye DAPI (blue). For easier interpretation, images obtained with α-PbSERA3N and α-PbSERA4M were
merged individually. Additional merges with images obtained with DAPI and α-PbEXP1 are shown for orientation. Scale bar: 5μm.
https://doi.org/10.1371/journal.ppat.1008891.g002
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the α-PbSERA4M antibody recognized distinct regions in liver-stage schizonts, and in cyto-
meres the two signals overlapped in the parasite. Upon release of parasites from the parasito-
phorous vacuole, both PbSERA4 and PbSERA3 are found inside the first-generation
merozoites with distinct localizations (Fig 2C). While PbSERA3 is also detected surrounding
the parasite in the parasitophorous vacuole, the α-PbSERA4M signal appears restricted to the
parasite. Together our findings show that PbSERA4 is expressed and proteolytically processed
in the liver and blood stages of infection and that protein expression is limited to the interme-
diate vertebrate host.
Absence of PbSERA4 delays the onset of blood-stage infection
To analyze the contribution of PbSERA4 to parasite development and life cycle progression,
we generated a Pbsera4 knockout line. In a P. berghei ANKA line constitutively expressing
GFP [26] the PbSERA4 gene was replaced by the Tgdhfr/ts positive selection cassette through
double homologous recombination (S4A Fig). After pyrimethamine-driven selection and clon-
ing by limited dilution, the gene deletion in the Pbsera4(-) line was confirmed by diagnostic
PCR, which showed the expected alteration of the genomic DNA (S4B Fig), RT-PCR, which
confirmed absence of PbSERA4 transcripts (Fig 3A), and western blot, which verified absence
of the PbSERA4 protein (S4C Fig).
Successful gene deletion indicated that although PbSERA4 transcripts were detected at high
levels during late blood stage development, PbSERA4 is not essential for asexual blood-stage
development. The effect of PbSERA4 deletion on blood-stage growth was specifically tested by
initiating infection of NMRI mice with intravenous delivery of infected red blood cells (Fig
3B). The time until appearance of infected cells in the blood and the growth rate of the Pbsera4
(-) line were indistinguishable from wildtype P. berghei. Gametocytes were readily detected in
the blood from mice infected with the Pbsera4(-) line, and we observed no defect in transmis-
sion of this line to mosquitoes, as evidenced by high numbers of sporozoites in the salivary
glands of Pbsera4(-)-infected mosquitoes (Fig 3C). These findings indicate that PbSERA4 is
dispensable for Plasmodium blood-stage development as well as transmission to and sporog-
ony in the mosquito vector.
To assess the impact that absence of PbSERA4 has on early stages of P. berghei development
in mammalian hosts, C57BL/6 mice were injected intravenously with 10,000 Pbsera4(-) sporo-
zoites. While wildtype-infected red blood cells appear in the blood three days after infection
with sporozoites, Pbsera4(-) parasites did not appear in blood smears until five days after infec-
tion (Fig 3D; S2 Table). After appearance in the blood, Pbsera4(-) parasites grew at rates com-
parable to wildtype P. berghei (Fig 3E). Infection using 10x more sporozoites or infection of
SD rats with Pbsera4(-) sporozoites resulted in similar, approximately two-day, delays in
appearance of blood-stage infection in comparison to infections with wildtype sporozoites (S2
Table).
To determine whether this delay in patency observed upon infection with Pbsera4(-) sporo-
zoites is due to inefficient infection of hepatocytes or reduced development of parasites in the
liver, we assessed the parasite burden in the livers of sporozoite-infected C57BL/6 mice using
quantitative PCR (Fig 3F). Pbsera4(-) parasites reached levels equivalent to wildtype parasites
in livers of infected animals 48 hours after infection. The parasite burden in livers infected by
wildtype parasites drops by 72 hours after infection due to egress and merozoite release.
Although the appearance of Pbsera4(-) parasites in the blood of sporozoite-infected animals is
delayed, the Pbsera4(-) parasites do not appear to be retained in the liver at 72 hours after
infection. The higher levels of detectable parasite RNA in livers of wildtype-infected animals
at 72 hours post-infection in comparison to Pbsera4(-)-infected animals is likely due to
PLOS PATHOGENS A Plasmodium cysteine protease required for efficient transition from the liver infection stage
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008891 September 21, 2020 7 / 20
contamination with blood-stage parasites that have grown in the blood of wildtype-infected
individuals by 72 hours post-infection. The comparable parasite burden near the onset of
egress, however, indicates that the delay in time to patency occurring during Pbsera4(-) infec-
tion is not due to reduced growth of the parasites in the liver.
PbSERA4 is required for efficient egress of liver-stage P. berghei
To further investigate the stage-conversion phenotype we see in Pbsera4(-)-infected mice, we
confirmed the ability of Pbsera4(-)-ANKA sporozoites to efficiently infect and grow in cells in
in vitro infection experiments (Fig 4). When Huh7 cells were infected, Pbsera4(-) sporozoites
developed into exo-erythrocytic forms (EEF) in numbers similar to those formed by wildtype
sporozoites (Fig 4A). Imaging of infected cells late in liver-stage development revealed that
while several wildtype parasites existed as merozoites that were detaching from one another
and were within the host cell cytoplasm, the Pbsera4(-) parasites that were imaged appeared to
remain as cytomeres (Fig 4B). When merosomes and parasite-containing detached cells were
Fig 3. Absence of PbSERA4 delays the time to appearance of Plasmodium-infected red blood cells. (A) Depletion of PbSERA4 transcripts in Pbsera4
(-)-ANKA parasites. cDNA from WT and Pbsera4(-) late-stage schizonts were used to verify the SERA4 specific PCR reaction.MSP1 transcript was used
as a positive control. RT-PCR was performed in the presence (+) or absence (-) of reverse transcriptase (RT). Parasite genomic DNA (gDNA) was
included as an amplification control. (B) Blood stage growth of Pbsera4(-)-ANKA P. berghei parasites. Naïve NMRI mice (n = 5) were injected
intravenously with 1,000 wildtype or 1,000 Pbsera4(-) P. berghei-infected erythrocytes. Infection was then monitored by daily examination of Giemsa-
stained blood smears to determine the parasitemia. ns, not significant (unpaired t-test, day 6 values). (C) Development of Pbsera4(-)-ANKA P. berghei
in mosquitoes. Sporozoites extracted from salivary glands of infected mosquitoes were quantified 17–25 days after infection. Data is presented as the
mean +/- SD. ns, not significant (paired t-test, n = 4 independent experiments). (D and E) Delayed patency following Pbsera4(-)-ANKA sporozoite
infection. C57BL/6 mice were infected intravenously with 10,000 sporozoites, and Giemsa-stained blood smears were monitored daily to determine
presence of parasites (D) ����, p<0.0001, Log-rank (Mantel-Cox) test, n = 10) and parasitemia (E) ����, p<0.0001 (unpaired t test, day 6 values). (F)
Pbsera4(-)-ANKA parasites exhibit no growth defects in infected livers. RNA was extracted from livers of C57BL/6 mice infected with 50,000 to 100,000
sporozoites at the indicated time points. Levels of Pb18s rRNA were normalized to levels of mouseHPRT RNA by qPCR. ns, not significant; �, p< 0.05
(unpaired t-test).
https://doi.org/10.1371/journal.ppat.1008891.g003
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collected from the supernatants of infected cultured cells following liver-stage infection, nota-
bly fewer Pbsera4(-)merosomes were detected (Fig 4C, S3 Table). Pbsera4(-)-infected cultures
generated approximately half the numbers of merosomes produced by wildtype-infected cul-
tures. When equal numbers of wildtype or Pbsera4(-)merosomes produced by cultured cells
were injected into mice, all mice developed a blood-stage infection (S3 Table), indicating that
the Pbsera4(-) liver-stage merozoites that are generated are as capable of infecting red blood
cells and establishing a blood-stage infection as wildtype merozoites. Together, these data indi-
cate that liver-stage Pbsera4(-) parasites are released inefficiently from infected cells, but that
they are infectious to red blood cells.
Fig 4. PbSERA4 is not required for liver-stage growth, but is needed for efficient egress from cultured cells. (A) Huh7 cells were infected
with sporozoites of the indicated P. berghei ANKA lines and fixed at the indicated time points. P. berghei exoerythrocytic forms (EEF) were
visualized and quantified by fluorescence microscopy. Data is presented as the mean +/- SD. (B) Infected Huh7 cells were fixed and imaged at
65 hours post-infection. At least 50 cells infected with each strain were visualized. More than a quarter of wildtype EEFs were at the advanced
stage shown in the upper panel, whereas in the Pbsera4(-)-infected cells, no individual merozoites could be detected in any cell, and none of the
Pbsera4(-) parasites had progressed further than the cytomere stage. (C) Merosomes and parasite-containing detached cells were collected from
the supernatants of infected Huh7 cells between 65 and 72 hours of liver-stage infection and quantified. Data compiled from five experiments
are shown and presented as means +/- SEM. � P<0.05 (ratio paired two-tailed t-test, n = 5 independent experiments). (D) Sub-inoculation
from pre-patent Pbsera4(-)-ANKA infected animals. C57BL/6 mice were infected intravenously with 10,000 wildtype-ANKA or Pbsera4
(-)-ANKA sporozoites. Blood was transferred from these infected mice to naïve NMRI mice at either 3 or 4 days after infection, and Giemsa-
stained blood smears were monitored daily to determine presence of parasites. ��, p<0.01, (Log-rank (Mantel-Cox) test, n = 5).
https://doi.org/10.1371/journal.ppat.1008891.g004
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If liver-stage merozoite egress is impeded in vivo, this could manifest either as a reduction
in the numbers of merozoites released from the liver or a delay in their release, and either
could cause the delay in the onset of blood-stage infection we observed in infected mice. To
distinguish between these two possibilities, we transferred blood from sporozoite-infected ani-
mals into naïve animals three days or four days after infection. At these time points, although
patent infection is not yet visible in blood smears of Pbsera4(-)-infected animals, all animals
that received the blood sub-inoculation developed a blood-stage infection (Fig 4D). This indi-
cates that merozoites have been released from the livers by this time, but that blood-stage
infection is below the level of detection by Giemsa-stained blood smears. Blood-stage parasites
did not appear in the Pbsera4(-)-sub-inoculated animals until three days after the appearance
of blood-stage parasites in animals receiving the wildtype sub-inoculation. These results illus-
trate that the numbers of blood-stage parasites present at this time in the Pbsera4(-)-sporozoite
infected animals is remarkably fewer in comparison to wildtype-sporozoite-infected animals.
These data together with the observed decrease in detectable parasite RNA in the livers of
Pbsera4(-)-infected animals at three days post-infection (Fig 3F) suggest that the timing of
liver-stage egress is not markedly delayed in a Pbsera4(-) infection, but rather that only few
liver-stage merozoites reach the blood.
Absence of PbSERA4 prolongs the prepatent period of the NK65 P. berghei
strain and leads to the upregulation of PbSERA3 during liver stage
development
To confirm that PbSERA4 is required for efficient P. berghei stage conversion from liver- to
blood-stage growth, we generated a second knockout line in the NK65 strain of P. berghei
using the same approach we used for the knockout line generated in the ANKA strain (S4D
Fig). When sporozoites of the resulting Pbsera4(-)-NK65 line were used to infect mice, the
Pbsera4(-)-NK65 parasites not only took longer to appear in the blood of infected animals in
comparison to wildtype NK65 parasites, but some animals infected with the knockout line
never developed a blood-stage infection (Fig 5A). The four-day delay in time to patent blood-
stage infection in the absence of PbSERA4 was likewise seen in P. bergheiNK65-infected SD
rats and also following infection by mosquito bite (S2 Table).
Targeted deletion of SERA genes has been shown to influence the expression of other SERA
genes [14, 32]. Absence of the serine-type PfSERA4 leads to upregulation of the essential ser-
ine-type PfSERA5 [32], and deletion of the serine-type PbSERA1 and PbSERA2 results in upre-
gulation of cysteine-type PbSERA3 [14]. We, therefore, examined the expression of the other
liver stage-expressed cysteine-type SERA, PbSERA3, in the absence of PbSERA4 at the end of
liver-stage development (Fig 5B). PbSERA3 is upregulated in Pbsera4(-)-NK65 in comparison
to the wildtype line in the livers of sporozoite-infected animals. Altering the expression of
PbSERA3may represent a compensatory mechanism by the parasite and may contribute to the
emergence of parasites in the blood in the absence of PbSERA4.
Infection with PbSERA4-deficient NK65 P. berghei sporozoites can confer
protection against reinfection
Following our observation that some mice stayed malaria-free once infected with either 1,000
or 10,000 Pbsera4(-)-NK65 sporozoites, we used these mice to test whether immunization with
Pbsera4(-)-NK65 sporozoites can confer sterile protection against challenge with wildtype
NK65 sporozoites. These protection assays could not be performed with the Pbsera4(-)-ANKA
line because all animals infected with this line developed a blood-stage infection, albeit
delayed. The two groups of mice (N = 10) were immunized with another two doses of either
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1,000 or 10,000 Pbsera4(-)-NK65 sporozoites, respectively (S4 Table, Fig 5C and 5D). Half of
the immunized mice were challenged by infection with wildtype sporozoites two months after
the last immunization. All mice immunized with 10,000 Pbsera4(-)-NK65 sporozoites were
protected and did not develop detectable blood-stage infections (Fig 5D). The mice immu-
nized with low doses of 1,000 Pbsera4(-)-NK65 sporozoites were modestly protected; three
mice of four developed a delayed blood-stage infection when challenged two months after the
last immunization (Fig 5C).
To assess long-term protection, the remaining immunized mice were challenged by injec-
tion of wildtype sporozoites 20 months after the last immunization (S4 Table). The six mice
that had shown protection after challenge at 2 months were also re-challenged at this time.
None of the mice that had received only three immunizations were protected at 20 months;
blood-stage parasites were detected in all of these animals after challenge. In contrast, all five
mice that received immunization doses of 10,000 Pbsera4(-)-NK65 sporozoites and were pro-
tected from the challenge at two months, were also protected against the re-challenge infection
Fig 5. Pbsera4(-)-NK65 parasites inefficiently initiate blood-stage infection and can confer protection against
sporozoite challenge infection. (A) Delayed patency following Pbsera4(-)-NK65 sporozoite infection. C57BL/6 mice
were infected intravenously with 10,000 sporozoites, and Giemsa-stained blood smears were monitored daily to
determine the presence of parasites. ����, p<0.0001, Log-rank (Mantel-Cox) test. (B) PbSERA3 is upregulated in the
liver in the absence of PbSERA4. PbSERA3 gene expression was analyzed in livers of C57BL/6 mice two days after
infection with wildtype and Pbsera4(-)-NK65 sporozoites. Relative gene expression was normalized to Pb18s and the
average of the wildtype-NK65 samples using the Pfaffl method. �, p<0.05 (unpaired t test, n = 4). (C and D) C57BL/6
mice were immunized three times with 1,000 or 10,000 Pbsera4(-)-NK65 sporozoites and were challenged two months
after the last immunization with wildtype NK65 sporozoites. Giemsa-stained blood smears were monitored daily to
determine the presence of parasites. ��, p<0.01; ����, p<0.0001, Log-rank (Mantel-Cox) test.
https://doi.org/10.1371/journal.ppat.1008891.g005
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at 20 months. This result indicates that the fourth exposure to pre-erythrocytic P. berghei con-
ferred long-lasting protection in these mice.
Our results with the NK65 knockout line confirm that the absence of PbSERA4 interferes
with the parasites’ ability to establish blood-stage infection. We further demonstrate that
although protection wanes over time, immunization with Pbsera4(-)-NK65 sporozoites can
confer sterile protection.
Discussion
Our studies have identified a role for PbSERA4 in the escape of Plasmodium parasites from the
liver stage of infection. All functional data on the Plasmodium SERA family thus far indicate
roles for these proteases in parasite egress [15, 17, 33]. Until now, of the Plasmodium SERA
family, only the contributions of PbSERA1 and PbSERA2 to liver-stage egress have been tested
[14]. Neither of these serine-type SERAs are necessary for Plasmodium exit from the liver [14],
and the specific cysteine proteases known to be needed for liver-stage egress [7] have remained
unidentified. The central finding of this study is that loss of PbSERA4 function reduces the effi-
ciency of liver-stage egress and weakens the transition from liver-stage growth to blood-stage
infection.
PbSERA4 is one of the cysteine-type SERAs, meaning that unlike the serine-type SERAs,
the papain-like catalytic site is intact and includes all key catalytic amino acid residues [21, 34].
The cysteine-type SERA genes have clear orthologs across Plasmodium species and the cyste-
ine-type SERA we describe here appears to have emerged in a common ancestor to all primate-
and rodent-infecting Plasmodium [21]. The predicted ortholog of PbSERA4 in P. falciparum is
PfSERA7, which is syntenic with PbSERA4 and shares the highest sequence identity with
PbSERA4 of the P. falciparum SERA genes. Furthermore, PfSERA7 has been shown to be dis-
pensable for blood-stage P. falciparum growth [16], which is consistent with our data showing
the PbSERA4(-) P. berghei lines grow proficiently in the blood.
Our expression and localization studies of PbSERA4 using a specific antibody and a parasite
line in which the endogenously encoded protein is fluorescently tagged show that PbSERA4 is
expressed in blood-stage and late-liver-stage Plasmodium. Previous studies demonstrated that
SERA family members in P. falciparum and P. berghei are proteolytically processed to their
active form [10, 18, 31, 33], and our data demonstrate that PbSERA4 appears also to be proteo-
lytically processed during infection. Processing of at least some SERA family members occurs
in the parasitophorous vacuole upon secretion of SUB1 [18]. In contrast to other liver-stage-
expressed SERAs [10, 14], PbSERA4 was only detected inside the parasite, but the localization
in liver-stage schizonts detected by both antibody staining and fluorescent tagging highly
resembles parasite endoplasmic reticulum [35]. This localization and the predicted N-terminal
signal peptide suggest that PbSERA4 is engaged by the parasites’ secretory pathway. The region
of PbSERA4 used to generate the α-PbSERA4M antibody contains a putative SUB1 cleavage
site; therefore, there is a possibility that this antibody may only recognize uncleaved protein
when the protein is in its native state after PFA fixation. Thus, if PbSERA4 cleavage products
are in the parasitophorous vacuole during liver infection, the antibody may have failed to
detect them.
Targeted deletion of PbSERA4 hindered the ability of P. berghei to transition from the liver
into the blood of infected animals. We observed that time until the appearance of blood-stage
parasites in animals following liver-stage infection increased in the absence of PbSERA4. The
length of this time delay depended on the P. berghei strain. The Pbsera4(-)-NK65 line was
more severely impaired than the Pbsera4(-)-ANKA line; patent infection was delayed by
approximately four days with the NK65 knockout line and two days with the ANKA knockout
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line. In some animals, the Pbsera4(-)-NK65 line even failed to establish blood-stage infection.
Pbsera4(-) liver-stage growth was unobstructed either in vivo or in cultured cells. Furthermore,
blood-stage growth of Pbsera4(-) parasites proceeded with normal growth rates regardless of
the route of infection. These results indicate that the restriction of Pbsera4(-) parasites occurs
between these two growth stages. Pbsera4(-)-infected cultured cells produce fewer merosomes,
which suggests a defect in egress of liver-stage merozoites from infected cells. This conclusion
would be consistent with the known egress functions of other SERA family members. The lev-
els of Pbsera4(-) parasite RNA in infected livers drop by 72 hours post-infection, indicating
that parasite-containing cells do not remain detectable in the liver in spite of few merozoites
reaching the bloodstream. An alternative possibility is that PbSERA4 is required for egress of
liver-stage merozoites from merosomes after they have entered the blood stream. PbSERA4 is
also expressed in blood-stage parasites, which is reported as well for PfSERA7. Our data con-
firm that PbSERA4 is not essential for asexual blood-stage development, as demonstrated for
PfSERA7 [16], and reveal that PbSERA4 is also expendable for gametocyte egress, which was
demonstrated by efficient infection of mosquitoes by the Pbsera4(-) lines. Whether PbSERA4
contributes to egress with functions for which other factors can compensate in its absence
remains to be determined.
The cysteine-type SERA genes form three phylogenetically distinct groups [36]. Group one,
represented by PbSERA5 and PfSERA8, in P. berghei and P. falciparum, respectively, is
required for egress of sporozoites from oocysts [15]. Group three, represented by PbSERA3
and PfSERA6, is essential for egress of merozoites from red blood cells [17]. PbSERA4 is within
group two, and our data suggests that this group contributes to egress of liver-stage merozoites
from the liver. In contrast to the studied representatives of the other two groups, PbSERA4 is
not vital to the process of parasite egress. In the absence of PbSERA4, a few parasites escape the
liver and successfully reach the blood. Another enzymatic protein that contributes to liver-
stage Plasmodium egress, P. berghei phospholipase, is also not strictly required for parasite
transition into the blood [8]. Because of the complexity and importance of this process for
establishing an infection in the mammalian host, Plasmodiummay have multiple mechanisms
by which to promote its transition from the liver into the blood. The upregulation of PbSERA3
in liver-stage Pbsera4(-)-NK65 parasites suggests that this other cysteine-type SERA may be
able to, in part, compensate for the loss of PbSERA4 in these parasites. While the localizations
of PbSERA3 and PbSERA4 do not always overlap, they do colocalize in the parasite in the cyto-
mere stage. While the function of PbSERA3 in the liver remains undefined, together these data
indicate that PbSERA3 could play a role in the ability of PbSERA4-deficient parasites to transi-
tion to the blood and may therefore contribute to liver-stage egress in wildtype parasites as
well.
Because multiple SERA proteins are expressed at the same time in both the blood and liver,
it has been proposed that they may influence the function of one another. For example, one
SERA could alter the function of another by affecting the recognition of its substrate or by
influencing its activation by proteolytic processing [34]. While this has been proposed in par-
ticular for the serine-type SERA proteins, we cannot formally exclude this as a possibility for
the cysteine-type SERAs. However, because PbSERA3 is essential for blood-stage development,
and processing of the corresponding P. falciparum ortholog, PfSERA6 is essential for its activ-
ity [17], we suspect that the processing and function of PbSERA3 is unaltered in parasites lack-
ing PbSERA4, at least in the blood stage of infection.
The failure of the Pbsera4(-)-NK65 line to establish blood-stage infection in some animals
provided an opportunity to assess the ability of this parasite line to elicit an immune response
that can protect animals against reinfection. Late-liver-stage-arresting P. berghei often confer
strong protection against re-infection [37], but often present the risk of breakthrough
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infections. The ability of these parasites to develop into late liver stages and elicit protective
responses indicates that perhaps this SERA gene could be deleted in combination with other
genes to achieve iterative attenuation at multiple checkpoints in the formation of first-genera-
tion merozoites, and this approach could lead to a safe and efficacious whole sporozoite vac-
cine strategy.
Taken together, these studies have revealed a role for PbSERA4 in exit of Plasmodium from
the liver. While not strictly essential for stage-conversion, PbSERA4 contributes to efficient
transition between liver- and blood-stage growth. As in egress of blood-stage merozoites, a
proteolytic cascade involving a distinct member, PbSERA4/PfSERA7, of the conserved family
of papain-like cysteine proteases contributes to exit of merozoites from the liver.
Materials and methods
Ethics statement
All animal work was conducted in accordance with the German ‘Tierschutzgesetz in der Fas-
sung vom 18. Mai 2006 (BGBl. I S. 1207)’, which implements directive 86/609/EEC from the
European Union and the European Convention for the protection of vertebrate animals used
for experimental and other scientific purposes. All appropriate measures were taken to reduce
the pain or discomfort of the animals, and the protocol was approved by the ethics committee
of the University of Heidelberg and Max Planck Institute for Infection Biology and by the state
authorities (Regierungspräsidium Karlsruhe G154/05 and Landesamt für Gesundheit und
Soziales G0469/09).
Experimental animals, cells and parasite lines
Naval Medical Research Institute (NMRI) mice, C57BL/6 mice, and Sprague Dawley (SD) rats
were purchased from Charles River Laboratories (Sulzfeld, Germany). Anopheles stephensi
mosquitoes were raised under a 14 h light/ 10 h dark cycle, 75% humidity and at 28 ˚C (non-
infected) or 20 ˚C (infected). The Huh7 hepatoma cell line was cultured in RPMI supple-
mented with 10% FCS, 100 U penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 10 mM
HEPES and 1× non-essential amino acids (NEAA) (Gibco). The HepG2 hepatoma cells were
cultivated in EMEM (Gibco) containing 10% fetal calf serum, 1% L-Glutamine, 1% Penicillin/
Streptomycin and 1% MEM Non-essential amino acids (PAA Laboratories GmbH, Pasching,
Austria). Wild-type P. berghei were either the P. berghei ANKA strain, ANKA clone 507 [26],
which expresses GFP, or P. bergheiNK65 [38].
Transcript detection and quantitation
Transcript detection in the various stages was performed as described [14]. RNA purification
was followed by cDNA synthesis and products were amplified using specific primers described
in S1 Table. Standard curves were generated for all primers using WT cDNA serial dilutions
and gave amplification efficiencies of 90–100%. Relative PbSERA3 gene expression was nor-
malized to Pb18s, and calculated with the Pfaffl method to account for differing primer effi-
ciencies [39]. The average Ct values from the wildtype-NK65-infected livers were used as
calibrators in this analysis.
Generation of sera4(-) and mCherry-tagged SERA4 parasites
Transgenic P. berghei lines were generated as described previously [14, 26]. For mCherry tag-
ging, the PbSERA4 locus was amplified with primers mCherry-SERA4for and mCherry-SER-
A4rev and integrated into B3D+mCherry [40] in frame with the mCherry coding sequence.
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For targeted disruption of PbSERA4, a replacement vector was generated through amplifica-
tion of genomic regions flanking PbSERA4 using primers SERA4rep1for and SERA4rep2rev
or SERA4rep3for and SERA4rep4rev and cloned into b3D.DT^H.^D (provided by Dr.
Andrew Waters, Glasgow University) flanking the Tgdhfr/TS expression cassette. P. berghei
parasites were transfected with linearized plasmids as described [14, 26], injected into naïve
NMRI mice and selected by oral pyrimethamine. Integration of the constructs was confirmed
by PCR with specific primer pairs (see supplementary information for details), and clonal lines
were isolated via limiting dilution. All oligonucleotide sequences are listed in S1 Table.
Generation of anti-PbSERA4 antibodies
The central (M) (Phe216-His365) region of PbSERA4 was amplified from P. berghei ANKA
cDNA. The resulting PCR product was ligated into pGEX6P-1 (Amersham, Bucking-hamp-
shire, England) and expressed in Escherichia coli BL21 cells (Stratagene) as glutathione S-trans-
ferase (GST) fusion proteins. Bacteria were lysed by sonication in PBS containing 10 mM
EDTA and CompleteTM protease inhibitor (Roche Molecular Biochemicals). GST-fusion pro-
teins were purified from the supernatant using glutathione-agarose as described by the manu-
facturer (Amersham Biosciences). 20μg of purified PbSERA4-N-GST or PbSERA4-M-GST
fusion protein was used to immunize six week old female NMRI mice by intraperitoneal injec-
tion along with complete Freund adjuvant, followed by multiple boosting immunizations. For
anti-PbSERA3N, blood samples were collected following immunization, to test serum reactiv-
ity against the SERA4-N protein. From a positive mouse spleen, cells were isolated and fused
to the mouse myeloma cell line X63Ag8.653. Supernatants were screened by indirect ELISA
and single-cell clones were isolated by limited dilution.
Immunofluorescence analysis
For analysis of PbSERA4 localization in late liver stages, infected HepG2 cells were fixed with
4% formaldehyde, permeabilized with ice-cold methanol and incubated with mouse anti-
PbSERA4M serum, rat anti-PbSERA3N serum [10] (1:200 in 10% FCS diluted in PBS) or a
chicken anti-Exp1 antibody. Bound antibodies were detected using fluorescently-conjugated
secondary antibodies (Molecular Probes, Leiden, The Netherlands). Labeled cells were exam-
ined by confocal microscopy using the Olympus FV1000 (SIM- scanner and spectral detection).
SDS-PAGE and western blot analysis
Blood-stage-schizont-infected red blood cells were enriched on a 55% Nycodenz gradient and
lysed in 0.15% saponin in PBS. Pelleted parasites were subsequently lysed in a TRIS-buffered
solution containing 150mM NaCl and 1.0% NP-40. For the merosome sample, loaded lysates
contained merosomes and detached cells collected from at least two wells of a 24-well dish
containing infected HepG2 cells. Merosomes and detached cells were lysed directly in
Laemmli sample buffer. Lysates were separated on 10% SDS-PAGE reducing gels and trans-
ferred to nitrocellulose membranes. Membranes were probed with mouse α-PbSERA4-M anti-
sera (1: 4000). Horseradish peroxidase-conjugated goat anti-mouse (1: 20.000, Pierce) were
used for detection, and bands were visualized by enhanced chemiluminescence Pico or Femto
Detection Kit (Pierce).
Parasite phenotyping during Plasmodium life cycle progression
To quantify patency or blood stage development, daily Giemsa-stained blood smears of
infected NMRI and C57BL/6 mice were counted. Exflagellation of microgametes were
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examined prior to mosquito feeding. For analysis of liver stage development, sporozoites were
added to cultured hepatoma cells, either Huh7 or HepG2 as indicated, incubated for two hours
at 37˚C, and washed. After fixation, exoerythrocytic forms (EEFs) were visualized by their
GFP expression or by using an anti-PbHSP70 antibody [41]. Merosomes and parasite-contain-
ing detached cells were collected 65–70 hours post infection when merosomes were visible in
the culture by light microscopy. To collect and quantify merosomes, the culture was gently agi-
tated by gently tapping the plate, and the culture medium was collected and centrifuged for 3
minutes at 2000 rpm. The pellet was resuspended in a low volume and merosomes were quan-
tified using a Neubauer chamber and fluorescence microscopy, which allowed identification
based on parasite GFP fluorescence. The parasite burden of Pbsera4(-) and WT infected livers
was determined as described [42, 43]. Briefly, C57Bl/6 mice were injected with 104 sporozoites
intravenously, and livers of infected animals were harvested at the indicated time points. Total
RNA was extracted and relative parasite levels were determined with quantitative–PCR by
comparing the mean Ct value of the P. berghei 18s ribosomal subunit to the mean Ct value of
theMus musculus hypoxanthine phosphoribosyl transferase (HPRT) in the generated cDNA.
Subinoculation was performed through transfer of blood taken from mice at day three or four
after sporozoite inoculation. Blood from infected mice was transferred into naïve mice by
intravenous injection. About 100μl PBS with one drop Heparin was mixed with two drops of
infected blood. The blood-PBS mixture then was injected intravenously into the tail of naïve
mice. The development of a patent parasitemia was analyzed by daily examination of Giemsa-
stained smears.
Immunization and parasite challenge experiments
Age-matched female C57BL/6 mice were immunized with 1,000 or 10,000 Pbsera4(-)-NK65
sporozoites, injected intravenously. Animals that remained malaria-free after the first immuni-
zation were given a second dose. Only animals that remained blood stage parasite-negative
after the first immunization and subsequent boost were used for the challenge experiments 2
and 20 months after the last immunization. Mice were challenged by intravenous injection of
10,000 WT sporozoites. At least three age-matched naïve animals were included to verify infec-
tivity of sporozoites during all challenge experiments. Parasitemia was monitored by daily
Giemsa-stained thin blood smears, starting from day 3 after immunization or challenge infec-
tion until at least day 14.
Statistical analyses
For assays quantifying parasites, RNA or merosomes, transgenic and wildtype P. berghei were
compared using two-tailed t-tests, and details are defined in the figure legends. Assays evaluat-
ing time to patency were analyzed using the Mantel-Cox test. All statistical analyses were per-
formed in GraphPad Prism version 7.
Supporting information
S1 Table. Oligonucleotides used in this study.
(PDF)
S2 Table. Infectivity of Pbsera4(-) sporozoites.
(PDF)
S3 Table. Infectivity of in vitro-generated Pbsera4(-) merosomes in mice. Huh7 cells in
6-well dishes were infected with P. berghei sporozoites of the indicated lines, and merosomes
and parasite-infected detached cells (collectively referred to as merosomes in table headings)
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were collected, quantified and the numbers indicated were injected intravenously into naïve
NMRI mice.
(PDF)
S4 Table. Immunizations of C57BL/6 mice with Pbsera4(-)-NK65 sporozoites. Animals
were infected intravenously with Pbsera4(-)-NK65 sporozoites. Those that remained negative
for blood-stage infection were boosted as indicated.
(PDF)
S1 Fig. Generation of transgenic PbSERA4-mCherry parasites. (A) Control PCRs for detec-
tion of SERA4 and control transcripts. P. berghei ANKA genomic DNA was used as a template
in PCRs run in parallel to those using cDNA as the template shown in Fig 1C. The product
sizes are as expected and match those amplified from cDNA. (B) Generation of an endoge-
nously encoded SERA4-mCherry fusion protein using a single cross-over insertion strategy.
An integration plasmid containing the region encoding the C-terminus of SERA4 (dark grey
box) fused to mCherry (red box) is targeted into the PbSERA4 genomic locus. The targeting
plasmid contains the 3’ UTR of PbDHFR/TS (light grey box) and the Tgdhfr/TS selectable
marker (white box). Integration results in a PbSERA4 gene that is expressed from its endoge-
nous promoter and tagged with mCherry followed by non-expressed truncated duplication of
the 3’ end of the gene. (C) Genotyping of the transgenic PbSERA4-mCherry parasite line with
the primers indicated in panel B resulted in expected products. (D) Confocal fluorescence
microscopy reveals expression of the SERA4-mCherry fusion protein (red) in blood stage par-
asites, including trophozoites (arrowheads) and gametocytes (asterisk). Scale bars, 8 μm.
(TIF)
S2 Fig. Stage-specific PbSERA-promoter-driven protein expression. The indicated 5’
regions upstream of the PbSERA4 or PbSERA5 coding sequences were cloned in front of GFP
into the P. berghei transfection plasmid pL0031 (right). GFP expression in P. berghei ANKA
parasites transfected with these constructs was monitored across the life cycle stages: midgut-
oocysts (oo), salivary gland sporozoites (sp), HepG2 cells infected with transgenic exo-erythro-
cytic parasites at indicated timepoints (EE) and erythrocytic stage (ES) were stained with
Hoechst 33342 and visualized by live microscopy.
(TIF)
S3 Fig. Validation of α-PbSERA4M antisera specificity. Recombinant PbSERA proteins
(1μg) spanning the central papain-like protease domain (M) were separated on a polyacryl-
amide gel and stained with Coomassie (top panel). Tags of the MBP-fusion proteins (lane1,2)
were cleaved off. The MBP-tag (grey arrow) and resulting proteins (black arrow) are indicated.
GST fusion proteins were insoluble and thus were purified by Prep-Cell purification (lane 3, 4)
GST-tags could therefore not be cleaved off. Thirty nanograms of these recombinant proteins
were run and transferred to a membrane that was subsequently probed with α-PbSERA4M
polyclonal antisera. α-PbSERA4M specifically recognized PbSERA4 and not other SERA pro-
teins.
(TIF)
S4 Fig. Generation and validation of clonal Pbsera4(-) parasites. (A) Experimental strategy
for targeted disruption of PbSERA4. The wildtype (WT) PbSERA4 genomic locus is targeted
with KpnI/SacII-linearized replacement plasmid containing 5’ and 3’ untranslated regions
adjacent to the SERA4 open reading frames and the dhfr/ts-positive selectable marker. Upon a
double cross-over homologous recombination, the PbSERA4 open reading frame is replaced
by the selectable marker, resulting in PbSERA4 knockout parasites termed Pbsera4(-). For
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genotyping, replacement-specific test and WT test primer combination are indicated by
arrows and expected fragments as lines. (B) Genotyping of the Pbsera4(-) disruption in P. ber-
ghei ANKA using PCR analysis. The primer combinations that amplify signals in the recombi-
nant locus (test1 and 2) of purified genomic DNA verified the successful replacement event.
The absence of a WT specific signal from Pbsera4(-) parasites confirms the purity of the clonal
populations. (C) PbSERA4 protein is not detected in the Pbsera4(-) line. Lysates of mixed-
stage infected erythrocytes were analysed by western blot using the anti-PbSERA4M antibody
(top). Anti-HSP70 antibodies were used as a loading control (bottom). Full length PbSERA4
and intermediate cleavage products are detected exclusively in the wildtype samples. (D) Gen-
otyping of the Pbsera4(-) disruption in P. bergheiNK65 using PCR analysis. The primer com-
binations that amplify signals in the recombinant locus (test 1 for and test 2 rev) of purified
genomic DNA verified the successful replacement event. The absence of a WT specific signal
from Pbsera4(-)-NK65 parasites confirms the purity of the clonal populations.
(TIF)
S1 Data. Spreadsheet containing the numerical data included within Figure panels 3B, 3C,
3E, 3F, 4A and 5B.
(XLSX)
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